IRCT20140211016554N4已完成2 期
Evaluation of the effectiveness of oral dapsone with intralesional antimoniate in treatment of cutaneous leishmaniasis in comparison with intralesional antimoniate alone
适应症
试验速览
- 阶段
- 2 期
- 状态
- 已完成
- 入组人数
- 100
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- 10 years 至 40 years（—）
- 性别
- All
入选标准
- •positive direct smear of the lesion in terms of leishman bodies
- •patient has indication of topical treatment according to the physician
- •less than six month has elapsed since the manifestation of lesion
- •patient has not received any previous treatment for cutaneous leishmaniasis
- •intervention group has normal values for CBC;G6PD;LFT
- •location of lesion is either on upper limbs or face
排除标准
- •sensitivity to glucantime (severe topical reaction, anaphylaxis).
- •absence of regular follow-ups
- •existence of secondary infection in lesion
- •use of other treatments during the study
- •dapsone side effects including methemoglobinemia, hemolytic anemia, agranulocytosis, peripheral neuropathy, hypersensitivity
研究者
相似试验
已完成
2 期
Dapson in acne vulgarisIRCT2017072035195N1Rasht University of Medical Sciences60
尚未招募
不适用
Efficacy of Dapsone and Azathioprine in patients with chronic IPT.CTRI/2016/02/006652Institution sponsored500
进行中（未招募）
不适用
A phase II trial assessing dapsone topical gel in the prevention and treatment of erlotinib associated rashThe study population are patients with non-small cell lung carcinoma eligible for treatment with erlotinib (TarcevaTM). A significant number of these patients develop acne-like rash as a side effect of erlotinib.EUCTR2006-000390-30-FIHelsinki University Central Hospital, Skin and Allergy Hospital30
尚未招募
2 期
Effect of Praval bhasma, Lakshadi guggulu and local application of Dashang Lepa with pinda tail on knee joint pain in Hemophilia patientsCTRI/2024/01/061535Central Council for Research in Ayurvedic Sciences
已完成
3 期
A clinical trial to study the safety & efficacy of the study drug in patients with ulcerative colitisCTRI/2010/091/000068COSMO Technologies Ltd100